Renkon is an innovative enterprise focusing on early screening of cancer, founded in August 2021 by a team of excellent doctors from Tsinghua University School of Medicine. The application of the new universal cancer early screening technology based on the cfDNA chromosomal opening interval solves the difficulty in early detection of cancer, resulting in low survival rate of patients in the middle and late stages, and cumbersome and painful pathological examination process of patients. It has the characteristics of high specificity and sensitivity, wide coverage of cancer type, simple operation, high flux and low cost. Make liquid biopsy biomedical technology can benefit the majority of patients to the greatest extent!